GILD - Gilead Sciences, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Gilead Sciences, Inc.

333 Lakeside Drive
Foster City, CA 94404
United States
650-574-3000
http://www.gilead.com

SectorHealthcare
IndustryDrug Manufacturers - Major
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Ms. Robin L. WashingtonCFO & Exec. VP2.12M2.05M1963
Mr. Kevin B. YoungAdvisory2.8MN/A1958
Mr. Gregg H. AltonInterim CEO & Chief Patient OfficerN/AN/A1966
Dr. John G. McHutchisonExec. VP of Research, Clinical R&D and Chief Scientific OfficerN/AN/AN/A
Sung LeeVP of Investor RelationsN/AN/AN/A
Amounts are as of December 31, 2017 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Gilead Sciences, Inc. discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a PI3K delta inhibitor for blood cancer; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and Lexiscan, an injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging. In addition, the company offers Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; Tamiflu, an oral antiviral capsule for the treatment of influenza A and B; AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it develops product candidates for the treatment of HIV/AIDS and liver diseases, hematology/oncology, inflammation/respiratory diseases, and others. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; Tango Therapeutics, Inc.; AELIX Therapeutics S.L.; TARGET PharmaSolutions, Inc.; Scholar Rock Holding Corporation; and Agenus Inc. The company was founded in 1987 and is headquartered in Foster City, California.

Corporate Governance

Gilead Sciences, Inc.’s ISS Governance QualityScore as of February 1, 2019 is 3. The pillar scores are Audit: 2; Board: 2; Shareholder Rights: 3; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.